[Federal Register Volume 62, Number 158 (Friday, August 15, 1997)]
[Notices]
[Pages 43737-43738]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-21722]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Science Board to the Food and Drug 
Administration.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA regulatory issues.
    Date and Time: The meeting will be held on September 30, 1997, 8:30 
a.m. to 4:30 p.m.
    Location: Washington Plaza Hotel, Washington room, 10 Thomas Circle 
NW., Washington, DC.
    Contact Person: Susan K. Meadows, Office of Science (HF-32), Food 
and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-
827-4591, or FDA Advisory Committee Information Line, 1-800-741-8138 
(301-443-0572 in the Washington, DC area), code 12603. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: Information will be presented to the board regarding the 
Biomaterials Forum (a process for information exchange addressing 
issues in biomaterials science), the FDA Information Retrieval System 
(FIRSt), the activities of the Science Board Subcommittee on 
Toxicology, and current status of FDA's implementation of the 
recommendations of the board's Subcommittee on FDA Research. General 
discussion will follow on the agency's research and science program 
plans, peer review programs, and collaborative scientific efforts.
    Procedure: On September 30, 1997, from 9:30 a.m. to 4:30 p.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person by 
September 1, 1997. Oral presentations from the public will be scheduled 
between approximately 3 p.m. and 4 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before September 1, 
1997, and

[[Page 43738]]

submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Closed Committee Deliberations: On September 30, 1997, from 8:30 
a.m. to 9:30 a.m., the meeting will be closed to permit discussion 
where disclosure would constitute a clearly unwarranted invasion of 
personal privacy (5 U.S.C. 552b(c)(6)). The board will discuss 
nominations for, and select recipients of, the 1997 FDA Scientific 
Achievement Awards. Such discussion in a public meeting would disclose 
information of a personal nature and would constitute a clearly 
unwarranted invasion of personal privacy.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 7, 1997.
William K. Hubbard,
Acting Deputy Commissioner for Policy.
[FR Doc. 97-21722 Filed 8-14-97; 8:45 am]
BILLING CODE 4160-01-F